2026年英国风湿病学会风湿性多肌痛治疗指南
该指南由英国风湿病学会依据GRADE和AGREE II框架制定,替代2009年版PMR指南,针对老年PMR患者提出糖皮质激素起始与减量、早期甲氨蝶呤、IL-6受体拮抗剂使用及骨保护等推荐,旨在优化疾病控制并减少激素相关损害。
要点
- 推荐糖皮质激素起始与减量方案,并提供加速减量选项。
- 考虑早期使用甲氨蝶呤,对减停激素困难者可选用IL-6受体拮抗剂。
- 所有PMR患者均应进行骨保护,并持续患者教育与激素毒性监测。
核心结论
- 指南旨在支持临床医生为PMR患者提供安全、有效和个体化诊疗,促进合理使用糖皮质激素并及时引入节约激素的治疗。
研究设计与样本
- 本指南依据英国风湿病学会《创建临床指南方案(v6.0)》制定,采用GRADE和AGREE II框架,替代2009年BSR/BHPR PMR指南。
主要发现
- 糖皮质激素仍是PMR治疗的基石,但许多患者减量期间复发并长期暴露于激素毒性。
- 指南纳入何时与PMR患者讨论或转诊风湿免疫科、激素起始与减量、早期甲氨蝶呤、IL-6受体拮抗剂使用及骨保护等关键推荐。
关键数值与推荐
- 推荐内容包括:何时讨论或转诊风湿免疫科;糖皮质激素起始与减量(含加速减量选项);考虑早期甲氨蝶呤;无法减停激素或应答不佳者使用IL-6受体拮抗剂;所有PMR患者进行骨保护。
临床怎么用
- 临床应依据指南个体化启动和减量糖皮质激素,对减停困难或应答不佳者及时考虑甲氨蝶呤或IL-6受体拮抗剂,并全程监测激素毒性及骨保护。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Polymyalgia rheumatica (PMR) is a common inflammatory rheumatic condition in older adults. Glucocorticoids (GCs) remain the cornerstone of treatment, but many people with PMR relapse during tapering and are exposed to prolonged GC therapy with associated toxicity. There is therefore a need for evidence-based strategies that optimize disease control while minimizing GC-related harm. This guideline was developed in line with the British Society for Rheumatology's Creating Clinical Guidelines Protocol (v6.0), using GRADE and AGREE II frameworks, and supersedes previously published 2009 BSR/BHPR PMR guidelines. Several key recommendations have been included in this guideline update. These include when to discuss or refer people with PMR to rheumatology; initiation of GCs and tapering with options for a faster GC taper; consideration of early methotrexate; IL-6 receptor antagonist use in people with PMR who are unable to taper GCs or have had an inadequate response; and bone protection in all people with PMR. Furthermore, the guideline emphazises the importance of ongoing patient education and counselling, monitoring for glucocorticoid toxicity and suggestions for when to refer people with PMR to secondary care. This guideline aims to support clinicians in delivering safe, effective and individualized care for people with PMR, while promoting judicious use of GCs and timely introduction of GC-sparing therapies where appropriate.
引用
- Toyoda T, Bhide S, Boland C, et al. The 2026 British Society for Rheumatology guideline for the treatment of polymyalgia rheumatica. Rheumatology (Oxford). 2026. PMID: 42869454. doi:10.1093/rheumatology/keag502
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。